|
목적 : To report our accumulation of experience and knowledge for ocular GVHD patients after allogenic BMT.
방법 : In this study, patients with hematologic diseases were received allogenic BMT from January 2009 to December 2012. We included patients who have been observed by ophthalmologist more than 2 years at least after transplantation. The frequency and subgroup analysis for patients with ocular GVHD was done. The overall prevalence for several variables were investigated and patients with ocular GVHD were analyzed to confirm risk factors for occurrence ocular GVHD from the medical records. The risk factors for ocular GVHD were compared with the risk factors for GVHD involving other organs.
결과 : Total 635 patients were included. The prevalence of ocular GVHD was 38.74%. The mean duration between BMT and occurrence of ocular GVHD was 225.7±194.3 days. There was significant difference in prevalence of ocular GVHD according to history of acute GVHD at other organ(p<0.001), hematologic diagnosis(p<0.001), classification of BMT(p=0.0057), ATG treatment as a prophylaxis(p<0.001), the number of involved organs except eye(p<0.001). The percentage of acutely involved other organs were skin(50.8%), gastrointestinal(35.0%), liver(12.2%) and chronically oral(84.2%), skin(46.8%), liver(40.2%).
결론 : The majority in patients after allogenic BMT was involved in GVHD. The prophylactic evaluations and treatments during early stage after transplantation are important. At the time of ocular exam, consideration of prophylactic and maintained treatments in hematology, history of acute GVHD, the number of involved organs is needed.
|